These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9070646)

  • 1. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease.
    Faucheux BA; Hauw JJ; Agid Y; Hirsch EC
    Brain Res; 1997 Feb; 749(1):170-4. PubMed ID: 9070646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease.
    Faucheux BA; Hirsch EC; Villares J; Selimi F; Mouatt-Prigent A; Javoy-Agid F; Hauw JJ; Agid Y
    J Neurochem; 1993 Jun; 60(6):2338-41. PubMed ID: 8492137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
    Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
    Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transferrin receptors in the parkinsonian midbrain.
    Morris CM; Candy JM; Omar S; Bloxham CA; Edwardson JA
    Neuropathol Appl Neurobiol; 1994 Oct; 20(5):468-72. PubMed ID: 7845532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paranigralis of control and Parkinson's disease brain.
    Yamada M; Yamada M; Richelson E
    Neuroscience; 1995 Jan; 64(2):405-17. PubMed ID: 7700529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?
    Mouatt-Prigent A; Karlsson JO; Agid Y; Hirsch EC
    Neuroscience; 1996 Aug; 73(4):979-87. PubMed ID: 8809817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.
    Parain K; Murer MG; Yan Q; Faucheux B; Agid Y; Hirsch E; Raisman-Vozari R
    Neuroreport; 1999 Feb; 10(3):557-61. PubMed ID: 10208589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease.
    Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y
    J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.
    Javoy-Agid F; Hirsch EC; Dumas S; Duyckaerts C; Mallet J; Agid Y
    Neuroscience; 1990; 38(1):245-53. PubMed ID: 1979431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hunot S; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2002 Oct; 83(2):320-30. PubMed ID: 12423242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
    Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
    Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys.
    Faucheux BA; Herrero MT; Villares J; Levy R; Javoy-Agid F; Obeso JA; Hauw JJ; Agid Y; Hirsch EC
    Brain Res; 1995 Sep; 691(1-2):115-24. PubMed ID: 8590043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?
    Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y
    J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease.
    Pearce RK; Owen A; Daniel S; Jenner P; Marsden CD
    J Neural Transm (Vienna); 1997; 104(6-7):661-77. PubMed ID: 9444566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases.
    Leveugle B; Faucheux BA; Bouras C; Nillesse N; Spik G; Hirsch EC; Agid Y; Hof PR
    Acta Neuropathol; 1996; 91(6):566-72. PubMed ID: 8781654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the altered expression of tyrosine hydroxylase and calbindin-D 28kD immunoreactivities and viability of neurons in the ventral tegmental area of Tsai following injections of 6-hydroxydopamine in the medial forebrain bundle in the rat.
    Tan Y; Williams EA; Lancia AJ; Zahm DS
    Brain Res; 2000 Jun; 869(1-2):56-68. PubMed ID: 10865059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iron transport in Parkinson's disease.
    Hirsch EC
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain.
    Yamada M; Groshan K; Phung CT; Yamada M; Hisamitsu T; Richelson E
    Brain Res Mol Brain Res; 1997 Feb; 44(1):12-20. PubMed ID: 9030693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.